Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Actinium Pharmaceuticals, Inc. (OTC: ATNM).

Full DD Report for ATNM

You must become a subscriber to view this report.


Recent News from (OTC: ATNM)

Actinium Appoints Robert N. Daly, Ph.D. to Newly Created Role of Vice President, Head of Clinical Operations
NEW YORK , Sept. 6, 2018 /PRNewswire/ --  Actinium Pharmaceuticals, Inc.   (NYSE AMERICAN: ATNM) today announced the appointment of Robert N. Daly , M.S., Ph.D., to the position of Vice President, Head of Clinical Operations, effective immediately. In this role, Dr. Daly will o...
Source: PR Newswire
Date: September, 06 2018 08:00
Actinium Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussions
NEW YORK , Sept. 4, 2018 /PRNewswire/ --  Actinium Pharmaceuticals, Inc.   (NYSE AMERICAN: ATNM) today announced that it will present at 2018 B . Riley FBR Healthcare Conference on Tuesday, September 4 th and at the Maxim Rights Offering Conference on Thursday, September 6 ...
Source: PR Newswire
Date: September, 04 2018 08:00
Actinium to Provide Update on Pivotal Phase 3 SIERRA Trial Following Positive Data Monitoring Committee Meeting
NEW YORK , Aug. 14, 2018 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.   (NYSE AMERICAN: ATNM) ("Actinium" or "the Company"), today announced that it will conduct a conference call on Wednesday, August 15, 2018 at 9:00 AM ET to provide an update on the Pivotal Phase 3 SIERRA Tr...
Source: PR Newswire
Date: August, 14 2018 16:05
Actinium Forms Nuclear Medicine Focused Advisory Board to Facilitate Pipeline Clinical Development and Iomab-B Commercial Planning
NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc.   (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), today announced that it has appointed the members of its Nuclear Medicine Clinical Advisory Board.  The following nuclear medicine physicians and scien...
Source: GlobeNewswire
Date: July, 17 2018 17:29
Actinium Pharmaceuticals (ATNM) Updates On Actimab-A MRD (Clinical trial for Minimal Residual Disease in Postremission AML Patients) - Slideshow
The following slide deck was published by Actinium Pharmaceuticals, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: July, 11 2018 13:42
Actinium to Host Webcast on July 10, 2018 to Discuss Actimab-A MRD clinical trial for Minimal Residual Disease in Postremission AML Patients
Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse with a need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM ET to discuss planned trial featuring Dr. Joseph Jurcic, Director of the Hematologic Malignanc...
Source: GlobeNewswire
Date: July, 09 2018 16:14
Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets
The most important weapon we as investors have in our arsenals is knowledge. Many of the people I've spoken with on Seeking Alpha and other forums have demonstrated keen awareness of the clinical pipeline for their company of interest. However, it is often difficult for them to place the resul...
Source: SeekingAlpha
Date: July, 09 2018 08:00
Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks
Stock Research Monitor: ACHN, ATNM, and APRI LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on AMRN sign up now at www.wallstequities.com/registration . On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading...
Source: ACCESSWIRE IA
Date: July, 02 2018 07:05
3 Things In Biotech, June 29: The Highs And Lows (Very, Very Lows) Of Drug Development
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Cara showcases their ability to end post-surgical pain Company: Cara Therapeutics ( CARA ) ...
Source: SeekingAlpha
Date: June, 29 2018 08:53
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies   Webcast to be held on July 10, 2018 at 8:00 AM ET to discuss planned trial featuring Dr. Joseph Jurcic, Director of the He...
Source: GlobeNewswire
Date: June, 28 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.440.41770.450.4175513,704
2018-12-130.470.430.470.429439,755
2018-12-120.450.4420.480.44406,856
2018-12-110.44580.440.4890.44415,243
2018-12-100.47080.43350.4770.43643,483

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on ATNM.


About Actinium Pharmaceuticals, Inc. (OTC: ATNM)

Logo for Actinium Pharmaceuticals, Inc. (OTC: ATNM)

Actinium Pharmaceuticals, Inc. ATNM.OB is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium and bismuth and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company s lead radiopharmaceutical Iomab TM B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is conducting a single, pivotal, multicenter Phase clinical study of Iomab B in refractory and relapsed Acute Myeloid Leukemia AML patients over the age of with a primary endpoint of durable complete remission. The company s second program, Actimab A, is continuing its clinical development in a Phase / trial for newly diagnosed AML patients over the age of in a single arm multicenter trial.

 

 

 

Current Management

  • Kaushik Dave / CEO
  • Dragan Cicic / COO, Chief Med. Officer
  • Corey Sohmer / VP, Fin.
  • Sergio Traversa / CFO, Interim CFO
  • Sergio Traversa / NonExecutive Director
  • Kaushik Dave /

Current Share Structure

  • Market Cap: $31,282,022 - 03/20/2018
  • Authorized: 200,000,000 - 01/28/2014
  • Issue and Outstanding: 80,025,639 - 11/03/2017

 


Recent Filings from (OTC: ATNM)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 16 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 26 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: February, 15 2018

 

 


Daily Technical Chart for (OTC: ATNM)

Daily Technical Chart for (OTC: ATNM)


Stay tuned for daily updates and more on (OTC: ATNM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ATNM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ATNM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ATNM and does not buy, sell, or trade any shares of ATNM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/